![Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey]()
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III SurveyVavricka, Stephan R.; Spasojevic, Milos; Rogler, Gerhard; Schoepfer, Alain M.; Seibold, Frank; Borovicka, Jan; Frei, Pascal; Zeitz, Jonas; Greuter, Thomas; Manser, Christine; Scharl, Michael; Misselwitz, Benjamin; Straumann, Alex; Michetti, Pierre; Biedermann, Luc · Digestive Diseases · 2017